Hympavzi Purple Book BLA 761369

BLA number
761369
Proprietary names
Hympavzi
Proper names
marstacimab-hncq
Applicant
Pfizer Inc.
Center
CDER
First observed release
2024-10-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Hympavzimarstacimab-hncq351(a)150MG/MLInjectionSubcutaneousPre-Filled SyringeRxLicensed2024-10-11
002Hympavzimarstacimab-hncq351(a)150MG/MLInjectionSubcutaneousAutoinjectorRxLicensed2024-10-11
003Hympavzimarstacimab-hncq351(a)75MG/0.5MLInjectionSubcutaneousPre-Filled SyringeRxLicensed2026-06-05
004Hympavzimarstacimab-hncq351(a)75MG/0.5MLInjectionSubcutaneousAutoinjectorRxLicensed2026-06-05

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2026-06-01N003Hympavzi351(a)RxPfizer Inc.
2026-06-01N004Hympavzi351(a)RxPfizer Inc.
2024-11-01U001Hympavzi351(a)RxPfizer Inc.
2024-11-01U002Hympavzi351(a)RxPfizer Inc.
2024-10-01N001Hympavzi351(a)RxPfizer Inc.
2024-10-01N002Hympavzi351(a)RxPfizer Inc.

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2026-06-01003Hympavzi351(a)RxLicensed2026-06-05
2026-06-01004Hympavzi351(a)RxLicensed2026-06-05
2024-10-01001Hympavzi351(a)RxLicensed2024-10-11
2024-10-01002Hympavzi351(a)RxLicensed2024-10-11